The Eurasian Patent Office has issued a notification of readiness to grant a patent covering the use of Piclidenoson for treating diseases associated with OCRL deficiency, including Lowe syndrome and Dent disease 2. The application is owned by Fondazione Telethon, Can-Fite’s research partner, under an agreement granting Can-Fite development, commercialization, and out-licensing rights for these indications. While the grant remains subject to completion of formalities, the allowance strengthens the intellectual property foundation supporting the company's development program and future partnering opportunities in this rare genetic disease indication. Can-Fite BioPharma Ltd. is a biotechnology company advancing proprietary small molecule drugs for oncological and inflammatory diseases.
